Revisions
To ensure that we are providing our clients with the industry’s best and most current clinical information, we complete a 'post-publication' process and receive feedback regarding opportunities to add additional information or, in rare cases, make revisions.
Below is information on revisions, corrections, or modifications to existing monographs that have been identified in the past 12 months.
Lorazepam - February 2012
Revision in the Dosage field of the Lorazepam monograph in Lexi-Drugs online and handheld applications and the following print publications Anesthesiology & Critical Care Drug Handbook, 10th edition, Drug Information Handbook for Oncology, 10th edition, and Geriatric Dosage Handbook, 17th edition. A typographical error in the source document (Mayo-Smith MF, Beecher LH, Fischer TL, et al, "Management of Alcohol Withdrawal Delirium. An Evidence-Based Practice Guideline," Arch Intern Med, 2004, 164(13):1405-12; published erratum appears in Arch Intern Med, 2004, 164(18):2068.) has been identified and that information has been corrected with this posting.
The monograph previously read:
Dosage: (only portion of field impacted is presented):
Alcohol withdrawal delirium (unlabeled use) (Mayo-Smith, 2004):
I.M.: 1-40 mg every 30-60 minutes until calm, then every hour as needed to maintain light somnolence
It has been revised to read:
Dosage: (only portion of field impacted is presented):
Alcohol withdrawal delirium (unlabeled use) (Mayo-Smith, 2004):
I.M.: 1-4 mg every 30-60 minutes until calm, then every hour as needed to maintain light somnolence
These changes have been automatically posted to online and hand-held reference sources, but text before the revision will persist in the current print editions.
Epinephrine - January 2012
Revision in the Dose and route of the Epinephrine monograph in the Medical Emergencies section in the following print publication Manual of Pediatric Dentistry, 1st edition
The monograph previously read:
Dose and route: (only portion of field impacted is presented):
IV: 0.01 mg/kg (0.1 mg/kg of 1:10,000 solution); not to exceed 0.5 mg every 20 minutes
It has been revised to read:
Dose and route: (only portion of field impacted is presented):
I.V.: 0.01 mg/kg (0.1 mL/kg of 1:10,000 solution); not to exceed 0.5 mg every 20 minutes
Mefenamic Acid - December 2011
Revision in the Dosage field of the Mefenamic Acid monograph in Lexi-Drugs online and handheld applications and the following print publications Drug Information Handbook, 20th edition (domestic and international versions), Drug Information Handbook for Dentistry, 17th edition, Drug Information Handbook for Psychiatry, 7th edition, Anesthesiology & Critical Care Drug Handbook, 10th edition, Quick Look Drug Book, 2012 edition, and Geriatric Dosage Handbook, 17th edition.
The monograph previously read:
Dosage: (only portion of field impacted is presented):
Children >14 years and Adults: Oral: 500 mg to start then 250 mg every 4 hours as needed; maximum therapy: 1 week
It has been revised to read:
Dosage: (only portion of field impacted is presented):
Children >14 years and Adults: Oral: 500 mg to start then 250 mg every 6 hours as needed; maximum therapy: 1 week
These changes have been automatically posted to online and hand-held reference sources, but text before the revision will persist in the current print editions.
Doxycycline - November 2011
Revision in the Dosage field of the Doxycycline monograph in Pediatric and Neonatal Lexi-Drugs online and handheld applications and the following print publications Pediatric & Neonatal Dosage Handbook, 18th edition (domestic and international versions)
The monograph previously read:
Dosage: (only portion of field impacted is presented):
Children ≥8 years:
Malaria:
Treatment: Oral, I.V.: 2 mg/kg/dose once daily for 7 days (maximum dose: 100 mg/dose) (CDC, 2009)
It has been revised to read:
Dosage: (only portion of field impacted is presented):
Children ≥8 years:
Malaria:
Treatment: Oral, I.V.: 2.2 mg/kg/dose twice daily for 7 days (maximum dose: 100 mg/dose) (CDC, 2009)
Ketotifen (Systemic) - September 2011
Revision in the Dosage field of the Ketotifen (Systemic) monograph in Lexi-Drugs online and handheld applications and the following print publications Drug Information Handbook, 20th edition (domestic and international versions), Drug Information Handbook for Dentistry, 17th edition, and Drug Information Handbook for Psychiatry, 7th edition.
The monograph previously read:
Dosage: (only portion of field impacted is presented):
Oral: Atopic asthma (prophylactic treatment):
Children 6 months to 3 years: Initial: 0.025 mg/kg once daily or in 2 divided doses for 5 days; Maintenance: 0.05 mg/kg twice daily
Children >3 years: Initial: 0.5 mg once daily or in 2 divided doses for 5 days; Maintenance: 1 mg twice daily
It has been revised to read:
Dosage: (only portion of field impacted is presented):
Oral: Atopic asthma (prophylactic treatment):
Children 6 months to 3 years: Initial: 0.05 mg/kg once daily or in 2 divided doses for 5 days; Maintenance: 0.05 mg/kg twice daily
Children >3 years: Initial: 1 mg once daily or in 2 divided doses for 5 days; Maintenance: 1 mg twice daily
These changes have been automatically posted to online and hand-held reference sources, but text before the revision will persist in the current print editions.
VIP (Etoposide) (Testicular Cancer) - July 2011
Revision in the Regimen field of the VIP (Etoposide) (Testicular Cancer) monograph in Lexi-Drugs online and handheld applications and the following print publications: Drug Information Handbook for Oncology, 9th edition and Quick Look Drug Book 2011 edition. A typographical error in the source document ("Correction: Incomplete Dosage Information in Article on Germ Cell Cancer," Ann Intern Med, 1988, 109(10):846) has been identified and that information has been corrected with this posting.
The monograph previously read:
Regimen: (only portion of field impacted is presented):
Variation 1:
Mesna: I.V.: 400 mg day 1 only
followed by I.V.: 1200 mg/day continuous infusion days 1 to 5
[total dose/cycle = 6400 mg]
It has been revised to read:
Regimen: (only portion of field impacted is presented):
Variation 1:
Mesna: I.V.: 400 mg/m² day 1 only
followed by I.V.: 1200 mg/m²/day continuous infusion days 1 to 5
[total dose/cycle = 6400 mg/m²]
These changes have been automatically posted to online and hand-held reference sources, but text before the revision will persist in the current print editions.
VIP (Vinblastine) (Testicular Cancer) - July 2011
Revision in the Regimen field of the VIP (Vinblastine) (Testicular Cancer) monograph in Lexi-Drugs online and handheld applications and the following print publications: Drug Information Handbook for Oncology, 9th edition and Quick Look Drug Book 2011 edition. A typographical error in the source document ("Correction: Incomplete Dosage Information in Article on Germ Cell Cancer," Ann Intern Med, 1988, 109(10):846) has been identified and that information has been corrected with this posting.
The monograph previously read:
Regimen: (only portion of field impacted is presented):
Variation 1:
Mesna: I.V.: 400 mg day 1 only
followed by I.V.: 1200 mg/day continuous infusion days 1 to 5
[total dose/cycle = 6400 mg]
It has been revised to read:
Regimen: (only portion of field impacted is presented):
Variation 1:
Mesna: I.V.: 400 mg/m² day 1 only
followed by I.V.: 1200 mg/m²/day continuous infusion days 1 to 5
[total dose/cycle = 6400 mg/m²]
These changes have been automatically posted to online and hand-held reference sources, but text before the revision will persist in the current print editions.
Bivalirudin - April 2011
Revision in the Dosage field of the Bivalirudin monograph in Lexi-Drugs online and handheld applications and the following print publications: Drug Information Handbook, 20th edition (domestic and international versions) and Anesthesiology & Critical Care Drug Handbook, 9th edition. A typographical error in the source document (Warkentin TE, Greinacher A, Koster A, et al, "Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)," Chest, 2008, 133(6 Suppl):340-80) has been identified and that information has been corrected with this posting.
The monograph previously read:
Dosage: (only portion of field impacted is presented):
Cardiac surgery in patients with acute or subacute (if surgery cannot be delayed) heparin-induced thrombocytopenia (unlabeled use; Warkentin, 2008): I.V.:
- Off-pump: Initial bolus: 0.75 mg/kg, followed by continuous infusion 1.75 mg/kg/hour to maintain ACT >300 seconds
- On-pump: Initial bolus: 1 mg/kg, followed by continuous infusion 2.5 mg/kg/hour; 50 mg bolus added to priming solution of cardiopulmonary bypass (CPB) circuit. Additional boluses of 0.1-0.5 mg may be given to maintain ACT >2.5 times baseline ACT. Note: Special maneuvers needed to prevent stasis and consequent clotting within CPB circuit during or after surgery
It has been revised to read:
Dosage: (only portion of field impacted is presented):
Cardiac surgery in patients with acute or subacute (if surgery cannot be delayed) heparin-induced thrombocytopenia (unlabeled use; Warkentin, 2008): I.V.:
- Off-pump: Initial bolus: 0.75 mg/kg, followed by continuous infusion 1.75 mg/kg/hour to maintain ACT >300 seconds
- On-pump: Initial bolus: 1 mg/kg, followed by continuous infusion 2.5 mg/kg/hour; 50 mg bolus added to priming solution of cardiopulmonary bypass (CPB) circuit. Additional boluses of 0.1-0.5 mg/kg may be given to maintain ACT >2.5 times baseline ACT. Note: Special maneuvers needed to prevent stasis and consequent clotting within CPB circuit during or after surgery
These changes have been automatically posted to online and hand-held reference sources, but text before the revision will persist in the current print editions.
Digoxin Immune Fab - February 2011
Revision in the Dosage field of the Digoxin Immune Fab monograph in Lexi-Drugs online and handheld applications and the following print publications Drug Information Handbook, 19th edition (domestic and international versions), Drug Information Handbook for Dentistry, 16th edition, Drug Information Handbook for Nursing, 12th edition, Drug Information Handbook for Advanced Practice Nursing, 11th edition and Anesthesiology & Critical Care Drug Handbook, 9th edition.
The monograph previously read:
Dosage: (only portion of field impacted is presented):
Based on steady-state serum digoxin concentration: Infants and Children ≤20 kg: May require smaller doses; calculate dose in milligrams, reconstitute with NS, and administer dose via tuberculin syringe
Step 1:
- Dose (mg) = [(serum digoxin concentration [ng/mL] x weight [kg]) / 10] x (mg/vial)
- Note: Digibind® 38 mg/vial or DigiFab™ 40 mg/vial
Alternatively, the following table gives an estimation of the amount of Digibind® needed based on the steady-state serum digoxin concentration.
It has been revised to read:
Dosage: (only portion of field impacted is presented):
Based on steady-state serum digoxin concentration: Infants and Children ≤20 kg: May require smaller doses; calculate dose in milligrams, reconstitute with NS, and administer dose via tuberculin syringe
Step 1:
- Dose (mg) = [(serum digoxin concentration [ng/mL] x weight [kg]) / 100] x (mg/vial)
- Note: Digibind® 38 mg/vial or DigiFab™ 40 mg/vial
Alternatively, the following table gives an estimation of the amount of Digibind® needed based on the steady-state serum digoxin concentration. These changes have been automatically posted to online and hand-held reference sources, but text before the revision will persist in the current print editions.
